Calogero Vetro

Catania, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.

Journal: British journal of haematology

Published: February 25, 2026

Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.

Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.

Journal: Haematologica

Published: January 14, 2026

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.

Journal: Biomolecules

Published: December 16, 2025

Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.

Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.

Journal: Genes

Published: December 13, 2025

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: December 04, 2025

Endovascular management of pelvic congestion syndrome in males: A report of 2 cases.

Endovascular management of pelvic congestion syndrome in males: A report of 2 cases.

Journal: Radiology case reports

Published: November 27, 2025

Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database.

Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 22, 2025

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Journal: Hematological oncology

Published: November 10, 2025

Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351.

Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351.

Journal: Leukemia & lymphoma

Published: October 31, 2025

Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk.

Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk.

Journal: Annals of hematology

Published: September 17, 2025

Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database.

Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database.

Journal: Hematology reports

Published: September 13, 2025

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Journal: Annals of hematology

Published: August 30, 2025

Showing 1-12 of 76

Last Updated: 09/26/2026